News Arch Biopartners Inc.

Equities

ACHFF

CA03938C1041

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 19:04:51 13/03/2026 GMT			5-day change	1st Jan Change
0.4975 ^USD	-4.16%		-13.70%	-43.68%

03-03	Arch Biopartners Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-09	Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease	CI

All News

03-03	Arch Biopartners Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
03-03	Arch Biopartners : 2026 Q1 Interim Financial Statements	PU
02-09	Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease	CI
02-09	Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease	AQ
01-29	Arch Biopartners : 2025 Q4 Interim Financial Statements	PU
01-29	Arch Biopartners Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
01-28	Arch Biopartners Inc. Auditor Raises 'Going Concern' Doubt	CI
01-16	Arch Biopartners Appoints Patrick Vink as Chairman	MT
01-16	Arch Biopartners Inc. Announces Appointment of Patrick Vink as Chairman of the Board and Retirement of Claude Allary from the Board of Directors	CI
01-16	Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board	AQ
12-17	Arch Biopartners Announces Ethics Approval for St. Michael's Hospital to participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide	AQ
12-16	Arch Biopartners Says Toronto's St Michael's Hospital Cleared to Participate in Phase II Trial Related To Kidney Injury	MT
12-16	Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide	AQ
12-16	Arch Biopartners Inc. Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide	CI
11-19	Arch Biopartners closes non-brokered private placement	RE
11-19	Arch Biopartners Closes Non-Brokered Private Placement	AQ
11-18	Arch Biopartners Inc. announced that it has received CAD 0.6 million in funding	CI
11-10	Arch Biopartners to Launch $500,000 Non-Brokered Private Placement Offering	MT
11-10	Arch Biopartners Inc. announced that it expects to receive CAD 0.5 million in funding	CI
11-10	Arch Biopartners Arranges Non-Brokered Private Placement	AQ
11-05	Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia	MT
11-05	Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia	AQ
11-05	Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia	CI
20/10/25	Arch Biopartners Inc.(TSXV:ARCH) dropped from S&P/TSX Venture Composite Index	CI
17/09/25	Arch Biopartners Acquires Platform to Develop New Drugs Targeting Chronic Kidney Disease	MT